Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109195 · ClinicalTrials.gov registry record
A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant
A clinical trial, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- 7
- Enrollment target
NCT05109195 is a clinical trial that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 7 participants.
The verdict
NCT05109195 was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
Interventions
- OTHER Standard of Care (SOC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-10-26 |
| Est. Completion | 2022-10-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109195
The ClinicalTrials.gov registry entry for NCT05109195 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care (SOC) is the first listed.
NCT05109195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05109195 about?
NCT05109195 is a clinical study titled "A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant". The purpose of this study is to assess the safety (adverse events, serious adverse events, deaths, suicidality) of participants with major depressive disorder (MDD) treated according to the standard of care (SOC).
What is the current status of trial NCT05109195?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2021-10-26. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT05109195?
The interventions under investigation include: Standard of Care (SOC) (OTHER).
Who is sponsoring clinical trial NCT05109195?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.